Carlos A. Ramos, MD
In phase I results published in the Journal of Clinical Investigation
, researchers have determined that CD30-specific chimeric antigen receptor (CAR) T cells could be used safely and induce durable complete responses in patients with Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).
“Our study demonstrates the tolerability, safety, and potential efficacy of CD30.CAR-Ts in CD30+ lymphoid malignancies,” Ramos et al wrote. “Appropriate tumor reduction and lymphodepletion before CD30.CAR-T infusion should enhance their clinical activity without increasing toxicity. Future exploration of the synergy between CD30.CAR-Ts and PD-1/PD-L1 blockade may also prove beneficial.”
Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes [published online August 14, 2017]. J Clin Invest. doi: 10.1172/JCI94306.
... to read the full story